



HUTCHISON CHINA MEDITECH LTD

**For Immediate Release**

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Notice of 2007 Preliminary Results**

**London, Thursday, 28 February 2008:** Chi-Med will be announcing its preliminary results for the year ended 31 December 2007 on Wednesday, 19 March 2008.

**Ends**

**Enquiries**

Chi-Med  
Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson  
Anthony Carlisle  
David Dible

Telephone: +44 (0) 20 7638 9571  
+44 (0) 7973 611 888  
+44 (0) 7967 566 919

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group focused on traditional Chinese medicine (“TCM”) based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med operates three core business segments: 1) China healthcare – the manufacture, distribution and marketing of pharmaceuticals and health supplements in China; 2) Drug R&D – the discovery and global development of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer products – global retailing and distribution consumer health and personal care products derived from TCM and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.